Effect and Mechanism of Curcumin on EZH2 - miR-101 Regulatory Feedback Loop in Multiple Myeloma

Multiple myeloma is the second most prevalent hematologic malignancy and thought to be incurable. Therefore, it's urgent to find new drugs for treatment. Some experiments have shown that curcumin might have great potential in treating multiple myeloma, while the mechanism is still unknown. EZH2...

Full description

Saved in:
Bibliographic Details
Published inCurrent pharmaceutical design Vol. 24; no. 5; p. 564
Main Authors Wu, Chuanqing, Ruan, Tuo, Liu, Weizhen, Zhu, Xiaojie, Pan, Juan, Lu, Wen, Yan, Chen, Tao, Kaixiong, Zhang, Weikang, Zhang, Chun
Format Journal Article
LanguageEnglish
Published United Arab Emirates 01.01.2018
Subjects
Online AccessGet more information

Cover

Loading…
Abstract Multiple myeloma is the second most prevalent hematologic malignancy and thought to be incurable. Therefore, it's urgent to find new drugs for treatment. Some experiments have shown that curcumin might have great potential in treating multiple myeloma, while the mechanism is still unknown. EZH2 and SUZ12 are the core proteins in PRC2 and their expressions are increased in various human cancers, including the poor prognostic multiple myeloma. Meanwhile, the regulation of miRNAs and EZH2 has been demonstrated in other cancer researches, like lung cancer, pancreatic cancer, leukemia and so on. To reveal the mechanism behind the anti-tumor effect of cucurmin in multiple myeloma. The effect of curcumin on the growth of MM cells was studied by MTT assay in the MM cell lines RPMI8226 and U266. Apoptosis was measured by Annexin V-FITC/PI double staining method. Western blotting, RT-PCR and luciferase activity assay were used to assess the expression of EZH2, SUZ12, miR-101 and downstream proteins such as E-cadherin, MMP9, c-Myc, cyclin D3, CDK4 and CDK6. Curcumin could significantly inhibite the proliferation of MM cells in a time- and concentrationdependent manner. Curcumin induced apoptosis by inhibiting the expression of EZH2, and the apoptosis rates were 16.42% and 25.62% when the RPMI8226 cells incubated with 5 and 10 µmol/L of curcumin. For U266 cells, the apoptosis rates were 15.25% and 21.28%. The up-regulation of miR-101 led to the lower expression of EZH2. In adverse, the expression of EZH2 induced lower expression of miR-101. The down-stream proteins of miR-101 were regulated by curcumin and EZH2 at the same time. Our experiments verified that the effect and mechanism of curcumin on multiple myeloma is via EZH2 - miR-101 regulatory feedback loop, which would lead us to a new way of investigating multiple myeloma and come up with new therapies in treating the disease.
AbstractList Multiple myeloma is the second most prevalent hematologic malignancy and thought to be incurable. Therefore, it's urgent to find new drugs for treatment. Some experiments have shown that curcumin might have great potential in treating multiple myeloma, while the mechanism is still unknown. EZH2 and SUZ12 are the core proteins in PRC2 and their expressions are increased in various human cancers, including the poor prognostic multiple myeloma. Meanwhile, the regulation of miRNAs and EZH2 has been demonstrated in other cancer researches, like lung cancer, pancreatic cancer, leukemia and so on. To reveal the mechanism behind the anti-tumor effect of cucurmin in multiple myeloma. The effect of curcumin on the growth of MM cells was studied by MTT assay in the MM cell lines RPMI8226 and U266. Apoptosis was measured by Annexin V-FITC/PI double staining method. Western blotting, RT-PCR and luciferase activity assay were used to assess the expression of EZH2, SUZ12, miR-101 and downstream proteins such as E-cadherin, MMP9, c-Myc, cyclin D3, CDK4 and CDK6. Curcumin could significantly inhibite the proliferation of MM cells in a time- and concentrationdependent manner. Curcumin induced apoptosis by inhibiting the expression of EZH2, and the apoptosis rates were 16.42% and 25.62% when the RPMI8226 cells incubated with 5 and 10 µmol/L of curcumin. For U266 cells, the apoptosis rates were 15.25% and 21.28%. The up-regulation of miR-101 led to the lower expression of EZH2. In adverse, the expression of EZH2 induced lower expression of miR-101. The down-stream proteins of miR-101 were regulated by curcumin and EZH2 at the same time. Our experiments verified that the effect and mechanism of curcumin on multiple myeloma is via EZH2 - miR-101 regulatory feedback loop, which would lead us to a new way of investigating multiple myeloma and come up with new therapies in treating the disease.
Author Pan, Juan
Zhang, Weikang
Wu, Chuanqing
Ruan, Tuo
Tao, Kaixiong
Zhang, Chun
Liu, Weizhen
Yan, Chen
Zhu, Xiaojie
Lu, Wen
Author_xml – sequence: 1
  givenname: Chuanqing
  surname: Wu
  fullname: Wu, Chuanqing
  organization: Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, China
– sequence: 2
  givenname: Tuo
  surname: Ruan
  fullname: Ruan, Tuo
  organization: Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, China
– sequence: 3
  givenname: Weizhen
  surname: Liu
  fullname: Liu, Weizhen
  organization: Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, China
– sequence: 4
  givenname: Xiaojie
  surname: Zhu
  fullname: Zhu, Xiaojie
  organization: Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, China
– sequence: 5
  givenname: Juan
  surname: Pan
  fullname: Pan, Juan
  organization: Department of pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, China
– sequence: 6
  givenname: Wen
  surname: Lu
  fullname: Lu, Wen
  organization: Department of Hematology, Union hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, China
– sequence: 7
  givenname: Chen
  surname: Yan
  fullname: Yan, Chen
  organization: Department of Hematology, Union hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, China
– sequence: 8
  givenname: Kaixiong
  surname: Tao
  fullname: Tao, Kaixiong
  organization: Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, China
– sequence: 9
  givenname: Weikang
  surname: Zhang
  fullname: Zhang, Weikang
  organization: Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, China
– sequence: 10
  givenname: Chun
  surname: Zhang
  fullname: Zhang, Chun
  organization: Department of Hematology, Union hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28322158$$D View this record in MEDLINE/PubMed
BookMark eNo1j8tKxDAUQIMozkN_Qa4fUM29SZN0KcOMI7QIg27cDGmSarVtSh-L-XsFdXU2hwNnxc672AXGbpHfEWp5j8KgQjIklFKouUCNSiqRnbElGi0SSUYt2GocPzlHylBesgUZQYSpWbLjtqqCm8B2HorgPmxXjy3ECjbz4Oa27iB2sH3bEyTQ1ocEOcIhvM-NneJwgl0IvrTuC_IYe_ixi7mZ6r4JUJxCE1t7xS4q24zh-o9r9rrbvmz2Sf78-LR5yJMy5WZKlKsyQVZrKdEiURmESo0j770pfeDeIXdOam59qjg6UalMa0pJZaUyLqU1u_nt9nPZBn_sh7q1w-n4f0rfqGtVQA
CitedBy_id crossref_primary_10_1007_s11899_019_00526_8
crossref_primary_10_3389_fonc_2020_608393
crossref_primary_10_1002_cam4_2108
crossref_primary_10_2174_0929867325666180629153141
crossref_primary_10_3390_ijms18081657
crossref_primary_10_1016_j_jtcme_2023_10_004
crossref_primary_10_1007_s11030_024_10833_9
crossref_primary_10_1111_bph_16237
crossref_primary_10_1016_j_biopha_2020_111078
crossref_primary_10_1016_j_jff_2023_105705
crossref_primary_10_1186_s13045_017_0492_1
crossref_primary_10_3390_nu11102376
crossref_primary_10_3390_antiox11122352
crossref_primary_10_2174_1871520620666200918113625
crossref_primary_10_1002_term_3187
crossref_primary_10_1080_10408398_2021_1968786
crossref_primary_10_1080_10408398_2022_2038540
crossref_primary_10_1186_s40364_018_0148_5
ContentType Journal Article
Copyright Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Copyright_xml – notice: Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
DBID NPM
DOI 10.2174/1381612823666170317164639
DatabaseName PubMed
DatabaseTitle PubMed
DatabaseTitleList PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-4286
ExternalDocumentID 28322158
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.5.
0R~
29F
36B
3V.
4.4
53G
5GY
69Q
7X7
88E
8AO
8FI
8FJ
8R4
8R5
AAEGP
ABEEF
ABJNI
ABUWG
ABVDF
ACGFO
ACGFS
ACITR
ACIWK
ACPRK
ADBBV
AENEX
AFKRA
AFRAH
AFUQM
AGJNZ
AHMBA
ALMA_UNASSIGNED_HOLDINGS
ANTIV
BENPR
BPHCQ
BVXVI
C1A
CCPQU
CS3
DU5
EBS
EJD
F5P
FYUFA
GH2
HMCUK
HZ~
IPNFZ
KCGFV
KFI
M1P
NPM
O9-
P2P
PQQKQ
PROAC
PSQYO
Q2X
RIG
UKHRP
ID FETCH-LOGICAL-b508t-6cf932a77441a122be3658c2ddd8bde0dc10cc470ad5601c3f697725269b68c52
IngestDate Thu Apr 18 08:39:07 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords SUZ12
multiple myeloma
Curcumin
PRC2
miR-101
EZH2
Language English
License Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-b508t-6cf932a77441a122be3658c2ddd8bde0dc10cc470ad5601c3f697725269b68c52
PMID 28322158
ParticipantIDs pubmed_primary_28322158
PublicationCentury 2000
PublicationDate 2018-01-01
PublicationDateYYYYMMDD 2018-01-01
PublicationDate_xml – month: 01
  year: 2018
  text: 2018-01-01
  day: 01
PublicationDecade 2010
PublicationPlace United Arab Emirates
PublicationPlace_xml – name: United Arab Emirates
PublicationTitle Current pharmaceutical design
PublicationTitleAlternate Curr Pharm Des
PublicationYear 2018
SSID ssj0012914
Score 2.3800018
Snippet Multiple myeloma is the second most prevalent hematologic malignancy and thought to be incurable. Therefore, it's urgent to find new drugs for treatment. Some...
SourceID pubmed
SourceType Index Database
StartPage 564
Title Effect and Mechanism of Curcumin on EZH2 - miR-101 Regulatory Feedback Loop in Multiple Myeloma
URI https://www.ncbi.nlm.nih.gov/pubmed/28322158
Volume 24
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Ja9tAFB6cFkovofteplBycdR6tI6PpSSYUodQHGJyMbNipbXktNbB-QX92X1PM7Jk09DlIoxGCDHv85u3fo-Qt0ozxSODzTGYZpR6EMhhZAMhDBKep8O4Hvc2PklHZ_GnaTLt9X52qpaqlXynrn_bV_I_UoV7IFfskv0HyW5eCjfgN8gXriBhuP6VjD31cF0rYbCFFydeYH1F9V1Vi7zATMDRxSjsB_1F_gV0IYPtrGfPY2b9GA4uKdTX_ueyXGLcY9wUF47X5lvpFfblNjvpcr4VA9dbBSDnlcvgV6K4ao7Euorez0Cuyk39T14_em7y63nbjHYxr-9Oc1Fe5qYbkGC8E5AwTonyLArArUm7WtZ1Sns0JR2VmTgW811Vjq4SRhUwsQlnaAi4Qe74COl94tQRIHVEvFzUMsbBS2DE8D-v7rBsN0t7ZC_jqClPMOrjs1HhkMV3yBv_Ve9v_CZklvbv2fFSamtlco_sezeDfnCYuU96pnhADk6d8NaHdNK23f04pAf0tGUwXz8kMwcsCsCiG2DR0tIGWLQsKAKLBtQDi7bAog2wKAKLwtMNsKgH1iNydnw0-TgK_CSOQIIBvwpSZcHOF-AqxEywMJQmAstVhVprLrUZaMUGSsXZQGj08FVkU_ArQpxeL1OukvAxuVWUhXlKqGWJlOjH2hSpFyNuM5bozCZacKZM9ow8cRs3Wzq6lVmzpc9vXHlB7rZAfEluW_h_m1dgLK7k61qSvwBp2mNv
link.rule.ids 786
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+and+Mechanism+of+Curcumin+on+EZH2+-+miR-101+Regulatory+Feedback+Loop+in+Multiple+Myeloma&rft.jtitle=Current+pharmaceutical+design&rft.au=Wu%2C+Chuanqing&rft.au=Ruan%2C+Tuo&rft.au=Liu%2C+Weizhen&rft.au=Zhu%2C+Xiaojie&rft.date=2018-01-01&rft.eissn=1873-4286&rft.volume=24&rft.issue=5&rft.spage=564&rft_id=info:doi/10.2174%2F1381612823666170317164639&rft_id=info%3Apmid%2F28322158&rft_id=info%3Apmid%2F28322158&rft.externalDocID=28322158